Hodges Capital Management Inc. Acquires 21,342 Shares of Halozyme Therapeutics, Inc. $HALO

Hodges Capital Management Inc. lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 18.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 134,696 shares of the biopharmaceutical company’s stock after buying an additional 21,342 shares during the period. Hodges Capital Management Inc.’s holdings in Halozyme Therapeutics were worth $8,705,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Measured Wealth Private Client Group LLC increased its position in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares during the last quarter. Abel Hall LLC boosted its position in Halozyme Therapeutics by 4.2% during the fourth quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock valued at $216,000 after purchasing an additional 129 shares during the last quarter. StoneX Group Inc. grew its stake in Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock valued at $246,000 after purchasing an additional 132 shares in the last quarter. Moran Wealth Management LLC grew its stake in Halozyme Therapeutics by 0.4% in the fourth quarter. Moran Wealth Management LLC now owns 35,596 shares of the biopharmaceutical company’s stock valued at $2,396,000 after purchasing an additional 151 shares in the last quarter. Finally, Coldstream Capital Management Inc. increased its position in shares of Halozyme Therapeutics by 1.9% during the 3rd quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after purchasing an additional 165 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on HALO shares. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, June 16th. Morgan Stanley lowered their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, UBS Group restated a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.60.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $79.45 on Monday. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The firm has a market cap of $9.42 billion, a price-to-earnings ratio of 28.58, a P/E/G ratio of 0.33 and a beta of 0.84. The stock’s fifty day moving average price is $69.41 and its two-hundred day moving average price is $69.46. Halozyme Therapeutics, Inc. has a one year low of $53.33 and a one year high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million during the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter in the previous year, the business posted $1.11 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the sale, the director owned 42,044 shares of the company’s stock, valued at $3,225,195.24. The trade was a 3.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 72,179 shares of company stock worth $5,052,400 in the last quarter. 2.50% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.